Table 3.
Commercial tests performance grouped by antibody detected and antigen used to.
| Type of test | Antibody detected | Antigen used for detection | Sensitivity | Specificity | Company | References |
|---|---|---|---|---|---|---|
| ELISA | Total antibodies (Ab) | Receptor Binding domain | 93.10% | 99.10% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (41) |
| 93.00% | 100.00% | (71) | ||||
| 97.50% | 100.00% | (72) | ||||
| IgM | Nucleocapsid protein | 77.30% | 100% | Zhuhai Livzon Diagnostics Inc. (China) | (73) | |
| 68.20% | 100.00% | Zhuhai Lizhu Reagent Co., Ltd. (China) | (69) | |||
| 46.10% | 82.00% | Guangzhou Darui Biotechnology Co., Ltd. (China) | (74) | |||
| Receptor Binding domain | 82.70% | 98.60% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (41) | ||
| 77.10% | 100.00% | Beijing Hotgen Biotech Co., Ltd. (China) | (69) | |||
| 92.50% | 100.00% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (72) | |||
| IgG | Nucleocapsid protein | 83.30% | 95.00% | Zhuhai Livzon Diagnostics Inc. (China) | (73) | |
| 64.70% | 99% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (41) | |||
| 70.10% | 100% | Zhuhai Lizhu Reagent Co., Ltd. (China) | (69) | |||
| 23.00% | 100% | Guangzhou Darui Biotechnology Co., Ltd. (China) | (74) | |||
| 88.80% | 100% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (72) | |||
| Receptor Binding domain | 74.30% | 100% | Beijing Hotgen Biotech Co., Ltd. (china) | (69) | ||
| Spike protein subdomain 1 | 67% | 96% | Euroimmun Medizinische Labordiagnostika (Germany) | (71) | ||
| Nucleocapsid protein and pike protein subdomain 2 | 88% | 97% | Mologic Ltd. (UK) | (39) | ||
| IgA | Spike protein subdomain 1 | 93% | 93% | Euroimmun Medizinische Labordiagnostika (Germany) | (71) | |
| LFIA | Total antibodies (Ab) | Receptor Binding Domain | 97.5% | 95.2% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (72) |
| IgM | Receptor Binding domain | 88.80% | 98.10% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (72) | |
| Unspecified | 43.20% | 98% | Artron Laboratories Inc. (Canada) | (11) | ||
| 57.10% | 100% | Zhuhai Livzon Diagnostics Inc. (China) | (73) | |||
| 55.80% | – | (75) | ||||
| IgG | Nucleocapsid protein | 86.30% | 99.50% | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) | (72) | |
| Unspecified | 14.40% | 100% | Artron Laboratories Inc. (Canada) | (11) | ||
| 81.30% | 100% | Zhuhai Livzon Diagnostics Inc. (China) | (73) | |||
| 54.70% | – | (75) | ||||
| IgM-IgG | Receptor Binding domain | 30% | 89% | Jiangsu Medomics Medical Technologies (China) | (99) | |
| 88.66% | 90.63% | (17) | ||||
| Unspecified | 82.40% | 100% | Zhuhai Livzon Diagnostics Inc. (China) | (76) | ||
| 90% | 100% | Dynamiker Biotechnology (China) | (71) | |||
| 90% | 100% | CTK Biotech (USA) | ||||
| 93% | 100% | AutoBio Diagnostics (China) | ||||
| 83% | 100% | Artron Laboratories Inc. (Canada) | ||||
| 18.40% | 91.70% | Vivachek Biotech (China) | (21) | |||
| 88.90% | 100% | Hangzhou Alltest Biotech Co., Ltd. (China) | (77) | |||
| CLIA | Total antibodies (Ab) | Receptor Binding domain | 96.30% | 99.30% | Xiamen InnoDx Biotech Co., Ltd. (China) | (72) |
| IgM | Nucleocapsid protein and spike protein | 48.10% | 100% | Shenzhen YHLO Biotech Co., Ltd. (China) | (78) | |
| 100% | 97.33% | (59) | ||||
| Receptor Binding domain | 86.30% | 99.30% | XIamen InnoDx Biotech Co., Ltd. (China) | (72) | ||
| IgG | Nucleocapsid protein and spike protein | 88.90% | 90.90% | Shenzhen YHLO Biotech Co., Ltd. (China) | (78) | |
| 100% | 99.56% | (59) |